EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors

Yuheng Gu, Qi Zhao iD

Molecular Diagnosis & Therapy · 2024-11 · 28 (6) · 669-702

DOI: 10.1007/s40291-024-00734-w ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Diagnosis & Therapy, online erschienen am 22.08.2024. Verfasst von Yuheng Gu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Neoplasms. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 208 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key R&D Program of China, Natural Science Foundation of Guangdong Province, Science and Technology Development Fund of Macau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, bispecific antibodies (BsAbs) have emerged as a promising therapeutic strategy against tumors. BsAbs can recruit and activate immune cells, block multiple signaling pathways, and deliver therapeutic payloads directly to tumor sites. This review provides a comprehensive overview of the recent advances in the development and clinical application of BsAbs for the treatment of solid tumors. We discuss the different formats, the unique mechanisms of action, and the clinical outcomes of the most advanced BsAbs in solid tumor therapy. Several studies have also analyzed the clinical progress of bispecific antibodies. However, this review distinguishes itself by exploring the challenges associated with bispecific antibodies and proposing potential solutions. As the field progresses, BsAbs hold promise to redefine cancer treatment paradigms and offer new hope to patients with solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificNeoplasmsHumansImmunotherapyAnimalsAntineoplastic Agents, Immunological

Substanzen

Antibodies, BispecificAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Cancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.
  • Cancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China. qizhao@um.edu.mo.
  • MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR, 999078, China. qizhao@um.edu.mo.

ORCID-Profile: Qi Zhao

Förderung

  • National Key R&D Program of China
  • Natural Science Foundation of Guangdong Province
  • Science and Technology Development Fund of Macau
  • University of Macau

Zitieren

APA

Gu, Y., & Zhao, Q. (2024). Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors. Molecular Diagnosis & Therapy, 28(6), 669-702. https://doi.org/10.1007/s40291-024-00734-w

Vancouver

Gu Y, Zhao Q. Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors. Molecular Diagnosis & Therapy. 2024;28(6):669-702. doi:10.1007/s40291-024-00734-w

BibTeX
@article{Gu2024,
  author = {Gu, Yuheng and Zhao, Qi},
  title = {Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors},
  journal = {Molecular Diagnosis & Therapy},
  year = {2024},
  volume = {28},
  number = {6},
  pages = {669--702},
  doi = {10.1007/s40291-024-00734-w}
}
Kostenlos starten →